177Lu-CTR-FAPI in Liver Cancer: NCT07229768 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Recruiting
Recruitment status
4
Planned enrollment
2026-11-30
Primary-completion proxy
Executive view
NCT07229768 evaluates 177Lu-CTR-FAPI in Liver Cancer. The disclosed sponsor is Shanghai First People's Hospital, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is AE, assessed over From enrolment to 12 months after the first dose.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07229768 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Liver Cancer landscape. Drug & Asset MCP drug_fetch was queried for 177Lu-CTR-FAPI, while Company & Deal Intelligence MCP organization_fetch was queried for Shanghai First People's Hospital.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07229768 | 177Lu-CTR-FAPI | Early Phase 1 / Recruiting | Shanghai First People's Hospital | China | AE From enrolment to 12 months after the first dose | 2026-11-30 |
| NCT07479732 | Apatinib Mesylate | Phase 1/2 / Recruiting | Peking University People's Hospital | China | Recommended Phase II Dose (RP2D) 6 weeks | 2027-03-05 |
| NCT07467122 | TCR-T cells targeting MAGE-A4(Sun Yat-Sen Memorial Hospital) | Phase 1 / Recruiting | Sun Yat-Sen Memorial Hospital | China | Number of participants with treatment-related Grade ≥3 cytokine release syndrome (CRS) or neurotoxicity assessed accord… Within 7 days after TCR-T cell infusion. | 2029-12-31 |
| NCT07460986 | Doxorubicin Hydrochloride | Phase 1/2 / Recruiting | Medica Scientia Innovation Research SL | Spain | Phase Ib: MTD and RP2D Up to 14 months | 2028-07-01 |
| NCT07459283 | 177Lu-INN805 | Early Phase 1 / Recruiting | FindCure Biosciences (ZhongShan) Co., Ltd. | China | Determine dose-limiting toxicity (DLT) 42 days after first dose | 2026-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07229768 is a Early Phase 1, recruiting study with 4 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “AE” over “From enrolment to 12 months after the first dose.” The retrieved endpoint description is: Adeverse Events.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 4 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Liver Cancer. These records do not establish direct evidence for NCT07229768 unless the registration number matches.
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase…
Phase 1; n=31; mOS = 33.8 Month Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42545754/
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Ace…
Phase 3; n=1016; ARR(Mean) = 0.182 Relapses per participant per year (Standard Error, 0.022); ARR(Mean) = 0.260 Relapses per participant per year (Standard Error, 0.029) Source: https://clinicaltrials.gov/ct2/show/results/NCT04121221
Real-world efficacy of fixed-dose weekly paclitaxel for AIDS-associated Kaposi Sarcoma: a 16-year cohort study in Rio de Janeiro, Brazil
Not Applicable; n=176; CR = 58.0 % Source: https://programme.aids2026.org/Abstract/Abstract/?abstractid=10933
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
177Lu-CTR-FAPI is indexed as Radionuclide Drug Conjugates (RDC) with target not reported biology and a global stage of Phase 1. The asset profile lists Xijing Hospital as an originator or developer.
Shanghai First People's Hospital is indexed in China with the website http://www.firsthospital.cn. The organization record is used to resolve sponsor identity. The record lists 19 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether 177Lu-CTR-FAPI is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07229768
Protocol source: https://clinicaltrials.gov/study/NCT07229768
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
177Lu-CTR-FAPI in Liver Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes AE and 2026-11-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
